Pleural Mesothelioma / Peritoneal Mesothelioma


Articles about advances in pleural mesothelioma therapy, clinical and cost considerations, and analysis of cases.

Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Liburn Road, Belfast BT9 7BL, Northern Ireland, UK.

Current concepts in malignant pleural mesothelioma.
Kaufman AJ, Pass HI. New York University Medical Center, Department of Surgery, 550 First Avenue, NBV-15N1, New York, NY 10016, USA.

Management options for malignant pleural mesothelioma: clinical and cost considerations.
Goudar RK. Department of Medicine, Duke University Medical Center, Durham, North Carolina 27701, USA.

New therapeutic options for mesothelioma.
Goudar RK. Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

Emerging drugs for mesothelioma.
Scagliotti GV, Selvaggi G. University of Turin, Department of Clinical & Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole, Orbassano (Torino), Italy.

New agents in the management of advanced mesothelioma.
Vogelzang NJ, Porta C, Mutti L. Nevada Cancer Institute, Las Vegas, NV 89135, USA.

Advances in malignant mesothelioma.
Robinson BW, Lake RA. School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia.

Malignant mesothelioma.
Robinson BW, Musk AW, Lake RA. Tumour Immunology Group, School of Medicine and Pharmacology, University of Western Australia, Australia.

[Therapeutic options in malignant pleural mesothelioma]
Serke M, Loddenkemper R. HELIOS Klinikum Emil von Behring, Lungenklinik Heckeshorn, Zentrum für Pneumologie und Thoraxchirurgie.

Malignant pleural mesothelioma.
Hughes RS. Division of Hematology/Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-8852, USA.

[Development in the treatment of malignant mesothelioma]
Bass P, Burgers JA.Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, afd Thorax-oncologie, Amsterdam.

Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
Pistolesi M, Rusthoven J. Section of Respiratory Medicine, Department of Critical Care, University of Florence, Viale G.B. Morgagni 85, 50134 Florence, Italy.

Malignant mesothelioma: current status and perspective in Japan and the world.
Hasegawa S, Tanaka F. Department of Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Japan.

Mesothelioma and asbestos-related pleural diseases.
Greillier L, Astoul P. Service d'ncologie Thoracique, Assistance Publique-Hôpitaux de Marseille, Faculté de Médecine, Université de la Méditerranée, Marseille, France.

[Pleural mesothelioma: impact of the staging for the therapeutic strategy]
Greillier L, Scherpereel A, Astoul P; Société de Pneumologie de Langue Francaise sur le Mésothéliome Pleural. Département des Maladies Respiratoires, Unité d'Oncologie Thoracique, Hôpital Sainte-Marguerite, Marseille, France.

[Environmental cancer: malignant pleural mesothelioma]
Margery J, Ruffié P. Pneumologie, Hôpital d'Instruction des Armées Percy, 101 avenue Henri Barbusse, 92140 Clamart, France.

[Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic]
Margery J, Ruffié P. Service de Pneumologie, Hôpital d'Instruction des Armées Percy, 101, avenue Henri-Barbusse, 92140 Clamart.

Management options for malignant pleural mesothelioma: clinical and cost considerations.
Goudar RK. Department of Medicine, Duke University Medical Center, Durham, North Carolina 27701, USA.

Carbone M, Strianese O, Theos K, Yang H. Thoracic Oncology Program, Cancer Research Center of Hawai'i, USA.

[Recommendations for the management of malignant pleural mesothelioma. The SPLF goes forward]
Godard P. Service des Maladies Respiratoires, CHU, Hôpital Arnaud de Villeneuve, Montpellier, France.

Biology and management of malignant pleural mesothelioma.
Zucali PA, Giaccone G. Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

[Malignant mesothelioma: A ten years experience.]
Lopes C, Sotto-Mayor R, Teixeira E, Almeida A. Serviço de Pneumologia, Hospital de Santa Maria, Lisboa.

[An analysis of 310 cases of pleural mesothelioma]
[Article in Chinese] [No authors listed] Editorial Board of Chinese Journal of Tuberculosis and Respiratory Disease, Beijing.

Phase I Studies of CBP501,a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors.
Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff DD, Kawabe T, Sharma S.

Articles about peritoneal mesotheliomas in children, advances in clinical research, current treatment options and epidemiology.

Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.
Klebe S, Mahar A, Henderson DW, Roggli VL. 1Department of Anatomical Pathology, Flinders University of South Australia, Adelaide, SA, Australia.

Primary peritoneal mesotheliomas in children: a clinicopathological and immunohistochemical study of eight cases.
Moran CA, Albores-Saavedra J, Suster S. Department of Pathology, M D Anderson Cancer Center, Houston, TX 77030, USA.

[Mortality from pleural and peritoneal cancer in a cohort of asbestos workers, many years after start of the exposure: possible role of fibers clearance]
Adesi FB, Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. SCDU Epidemiologia dei Tumori, Università di Torino, Via Santena 7, 10126, Torino, Italia.

Biological characteristics of cancers involving the serosal cavities.
Davidson B. Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Center, Montebello N-0310 Oslo, Faculty Division Radiumhospitalet, the Medical Faculty, University of Oslo, Oslo, Norway.

[Malignant peritoneal mesothelioma tumours. Evolution, treatment, prognosis]
Scripcariu V, Dajbog E, Radu I, Ferariu D, Pricop A, Grigoraş M, Dragomir C. Universitatea de Medicina şi Farmacie Gr. T. Popa Iaşi Facultatea de Medicină, Clinica a III-a Chirurgicală şi Centrul de Cercetare în Chirurgia Oncologică şi Training in Chirurgie Generală

Mesothelioma: you do not have to work for it.
Ampleford EJ, Ohar J. Center for Human Genomics, Wake Forest University, School of Medicine, Winston-Salem, North Carolina, USA.

Peritoneal mesothelioma: a review.
Bridda A, Padoan I, Mencarelli R, Frego M. Clinica Chirurgica I, Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, Via Giustiniani 2, Policlinico III Piano, 35128 Padova, Italy.

Advances in clinical research and management of diffuse peritoneal mesothelioma.
Deraco M, Baratti D, Zaffaroni N, Cabras AD, Kusamura S. Department of Surgery, National Cancer Institute, Milan, Italy.

[Malignant peritoneal mesothelioma]
Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C. Clinica aIII-a Chirurgicală si Centrul de Cercetare in Chirurgia Oncologică si Training in Chirurgie Generală, Spitalul "Sf. Spiridon", U.M.E "Gr. T. Popa" Iasi.

Sex difference in diffuse malignant peritoneal mesothelioma.
Yan TD, Popa E, Brun EA, Cerruto CA, Sugarbaker PH. Washington Cancer Institute, Washington, DC 20010, USA.

The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma.
Davidson B, Risberg B, Berner A, Bedrossian CW, Reich R. Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway.

Epidemiology of peritoneal mesothelioma: a review.
Boffetta P. International Agency for Research on Cancer, Lyon, France.

Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
Yan TD, Yoo D, Sugarbaker PH. Peritoneal Surface Malignancy Program, 106 Irving Street, NW, Suite 3900N, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.

Comprehensive management of diffuse malignant peritoneal mesothelioma.
Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA.

Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
Garcia-Carbonero R, Paz-Ares L. Division of Medical Oncology, Hospital Severo Ochoa, Av. Orellana s/n, 28911 Leganés, Madrid, Spain.

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C. National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264 USA.

Peritoneal benign mesothelioma during and after two pregnancies.
van Bijsterveldt C, Willemsen W, Bulten J.

Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium.
Hassan R, Alexander R. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264, USA.

Malignant peritoneal mesothelioma.
Bani-Hani KE, Gharaibeh KA. Department of Surgery, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Peritoneal mesothelioma.
Hesdorffer ME, Chabot J, DeRosa C, Taub R. Mesothelioma Applied Research Foundation, Santa Barbara, CA, USA.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Thoracic Oncology Program and Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, MRC-4W, 12902 Magnolia Drive, Tampa, FL 33612-9497, USA.


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376